Skip to content
HowShorted

HTG MOLECULAR DIAGNOSTICS, INC short interest in 2019

In 2019, HTG MOLECULAR DIAGNOSTICS, INC's disclosed short interest ran from 11.24% of shares outstanding on 15 Jan 2019 to 3.89% on 31 Dec 2019, a change of -7.35 percentage points. The year's high was 12.95% on 31 May 2019 and its low 3.89% on 31 Dec 2019, averaging 9.91% across 24 twice-monthly settlement dates. FINRA's days-to-cover figure peaked at 27.37 days on 14 Jun 2019. Full history: HTG MOLECULAR DIAGNOSTICS, INC.

Cite this page
Plain
Wikipedia
BibTeX

By year: 2018 · 2019 · 2020 · 2021 · 2022

Aggregate net short position time series for HTG MOLECULAR DIAGNOSTICS, INC in 2019

2019 in figures

Start of year
11.24% (15 Jan 2019)
End of year
3.89% (31 Dec 2019)
Change
-7.35 pp
High
12.95% (31 May 2019)
Low
3.89% (31 Dec 2019)
Average
9.91%
Highest days to cover
27.37 (14 Jun 2019)
SEC filings marked
9

Every report in 2019

HTG MOLECULAR DIAGNOSTICS, INC short interest in 2019
SettlementShort interestDays to coverFilings since previous
15 Jan 201911.24%16.78results (8-K)
31 Jan 201911.32%9.38
15 Feb 201910.53%7.78
28 Feb 201910.77%7.22
15 Mar 201911.98%7.5410-K filed, results (8-K)
29 Mar 201911.30%14.20
15 Apr 201911.99%8.52
30 Apr 201912.63%19.50
15 May 201912.74%14.9610-Q filed, results (8-K)
31 May 201912.95%17.73
14 Jun 201912.54%27.37
28 Jun 201912.14%11.91
15 Jul 201911.06%11.46
31 Jul 201911.10%16.33
15 Aug 201910.78%11.2610-Q filed, results (8-K)
30 Aug 201910.19%18.61
13 Sep 20199.04%9.49
30 Sep 20199.65%4.91
15 Oct 20198.44%6.65
31 Oct 20199.17%13.80
15 Nov 20194.33%7.9310-Q filed, results (8-K)
29 Nov 20194.13%9.89
13 Dec 20193.94%10.36
31 Dec 20193.89%4.51

See also: HTG MOLECULAR DIAGNOSTICS, INC's full history · most shorted US stocks of 2019 · today's US league.

About this data

US short interest data: FINRA (finra.org), shown as reported shares short divided by SEC-reported shares outstanding for each settlement date. FINRA® is a registered trademark of the Financial Industry Regulatory Authority, Inc. This site is not affiliated with or endorsed by FINRA or the SEC; displayed for personal reference, bulk redistribution is not permitted (see terms). Nothing here is investment advice. Method: methodology.